Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s
Digest more
In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.
Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback